STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.

Wang, Wenjun; Edington, Howard D; Rao, Uma N M; Jukic, Drazen M; Wang, Hong; Shipe-Spotloe, Janice M; Kirkwood, John M

Wang, Wenjun; Edington, Howard D; Rao, Uma N M; Jukic, Drazen M; Wang, Hong; Shipe-Spotloe, Janice M; Kirkwood, John M.

Affiliation

Wang W; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213-2584, USA.

J Invest Dermatol ; 128(8): 1997-2002, 2008 Aug.

Article in En | MEDLINE | ID: mdl-18305569

Subject(s)

Biomarkers, Tumor/metabolism; Interferon-alpha/therapeutic use; Melanoma/metabolism; Nevus/metabolism; STAT3 Transcription Factor/metabolism; Skin Neoplasms/drug therapy; Skin Neoplasms/metabolism; Biomarkers, Tumor/genetics; Biopsy; Disease Progression; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors/therapeutic use; Melanoma/drug therapy; Melanoma/pathology; Nevus/drug therapy; Nevus/pathology; STAT1 Transcription Factor/genetics; STAT1 Transcription Factor/metabolism; STAT3 Transcription Factor/genetics; Skin Neoplasms/pathology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Biomarkers, Tumor / Interferon-alpha / STAT3 Transcription Factor / Melanoma / Nevus Limits: Humans Language: En Journal: J Invest Dermatol Year: 2008 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google